Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
ANK-700 by Anokion for Relapsing Remitting Multiple Sclerosis (RRMS): Likelihood of Approval
ANK-700 is under clinical development by Anokion and currently in Phase I for Relapsing Remitting Multiple Sclerosis (RRMS). According to...